Suzhou Pilot Biotechnology
An industrial biotechnology company engaged in the development, production, and sales of health care products
About Suzhou Pilot Biotechnology
Suzhou Pilot Biotechnology Co., Ltd. (Leadermetbio), established in June 2015, operates at the forefront of the synthetic biology sector, focusing on replacing traditional chemical manufacturing with green, bio-based production methods. The company was founded by Dr. Xie Xinkai, a notable figure in the biotechnology field. Dr. Xie earned his Ph.D. from the University of California, Los Angeles, and was a postdoctoral fellow under Professor Jay Keasling, a foundational figure in synthetic biology. His background includes being the primary inventor of the biosynthesis of the cholesterol-lowering drug simvastatin and a recipient of the U.S. Presidential Green Chemistry Challenge Award in 2012.
The firm's core business involves the research, development, production, and sale of products for the pharmaceutical, nutritional supplement, and animal health markets. It utilizes an AI-driven synthetic biology platform that integrates gene editing, enzyme engineering, metabolic engineering, and fermentation optimization to develop efficient microbial strains and production processes. This model allows the company to provide bio-manufactured products to other businesses, serving as a key supplier in their respective value chains. Revenue is generated through the sale of these bio-synthesized products.
Pilot Biotechnology's product portfolio is extensive, including items such as the veterinary antibiotic intermediate D-ethyl ester, the feed additive active vitamin D3, and the anti-aging ingredient NMN. The company has successfully industrialized over 20 biosynthetic processes and operates multiple production bases, including a significant facility in Hunan that began production in 2023 and has a total capacity exceeding 10,000 tons. This allows the company to export products to more than 20 countries. To support its global reach, the company maintains a research and development headquarters in Suzhou, an R&D center in the United States, and production facilities in Hunan and Anhui.
Significant milestones include the establishment of its Hunan production base in October 2017, the opening of its U.S. R&D center in August 2019, and the acquisition of Anhui Libo Pharmaceutical Co., Ltd. in June 2023 to expand its raw material production capabilities. The company has also secured substantial funding through multiple rounds, including a Series D round in August 2023 and a subsequent D+ round of over 100 million yuan to accelerate commercialization and global market expansion.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotechnology, Health Diagnostics, Synthetic Biology, Hard Tech, biomanufacturing, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES D✓Equity / VC | Aug 2023 | $28M | $110M | Lilly Asia Ventures · Sherpa Venture Partners | ↗ |
| SERIES CEquity / VC | Feb 2022 | $14M | $55M | Lilly Asia Ventures | — |
Growth signals
Latest recorded traffic for Suzhou Pilot Biotechnology is 150 monthly website visits, down 91.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Suzhou Pilot Biotechnology in the Suzhou Shi ecosystem
The Suzhou Pilot Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Lilly Asia Ventures
Sherpa Venture Partners
Other known investors1 additional known investor
Asia Green Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Pilot Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Pilot Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










